Invatec expands its interventional reach into the U.S.
Invatec, a Roncadelle, Italy-based provider of vascular interventional products, has formally launched its U.S. operations with a new headquarters and chief.
The U.S. headquarters in Bethlehem, Pa., will now be responsible for the sales, marketing, clinical, regulatory and distribution of the company’s minimally-invasive diagnostic and therapeutic products. Invatec said its products are used by interventional cardiologists, radiologists, vascular surgeons and other vascular specialists.
The company also said that it has appointed Jack Springer as president to lead U.S. operations. Springer began his career in sales at Abbott Laboratories before joining Cordis Endovascular, where he worked for 12 years in positions of increasing responsibility leading to his appointment as general manager for Cordis Endovascular. Most recently, he served as president and CEO at Neuromonics.
Invatec currently offers a percutaneous transluminal angioplasty (PTA) balloon product line and a thrombus management catheter available for sale in the U.S., including: Amphirion Deep 0.014” PTA balloon catheter; Submarine Plus 0.018” PTA balloon catheter; Admiral Xtreme 0.035” PTA balloon; and Diver CE 0.014” RX clot extraction catheter.
The company said it currently has a pivotal IDE (Investigational Device Exemption) clinical trial, ARMOUR, underway at 25 investigational sites in the U.S. and Europe, to assess the safety and efficacy of a proximal protection device, Mo.Ma, for use in carotid stenting with FDA approved carotid stents.
Mo.Ma protects the brain from embolization by two atraumatic balloons, blocking antegrade blood flow from the common carotid artery and retrograde blood flow from the external carotid artery.
The U.S. headquarters in Bethlehem, Pa., will now be responsible for the sales, marketing, clinical, regulatory and distribution of the company’s minimally-invasive diagnostic and therapeutic products. Invatec said its products are used by interventional cardiologists, radiologists, vascular surgeons and other vascular specialists.
The company also said that it has appointed Jack Springer as president to lead U.S. operations. Springer began his career in sales at Abbott Laboratories before joining Cordis Endovascular, where he worked for 12 years in positions of increasing responsibility leading to his appointment as general manager for Cordis Endovascular. Most recently, he served as president and CEO at Neuromonics.
Invatec currently offers a percutaneous transluminal angioplasty (PTA) balloon product line and a thrombus management catheter available for sale in the U.S., including: Amphirion Deep 0.014” PTA balloon catheter; Submarine Plus 0.018” PTA balloon catheter; Admiral Xtreme 0.035” PTA balloon; and Diver CE 0.014” RX clot extraction catheter.
The company said it currently has a pivotal IDE (Investigational Device Exemption) clinical trial, ARMOUR, underway at 25 investigational sites in the U.S. and Europe, to assess the safety and efficacy of a proximal protection device, Mo.Ma, for use in carotid stenting with FDA approved carotid stents.
Mo.Ma protects the brain from embolization by two atraumatic balloons, blocking antegrade blood flow from the common carotid artery and retrograde blood flow from the external carotid artery.